KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $1.1 billion.

  • Moderna's Capital Expenditures fell 78.15% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.0 million, marking a year-over-year decrease of 9.88%. This contributed to the annual value of $1.1 billion for FY2024, which is 48.66% up from last year.
  • Latest data reveals that Moderna reported Capital Expenditures of $1.1 billion as of FY2024, which was up 48.66% from $707.0 million recorded in FY2023.
  • In the past 5 years, Moderna's Capital Expenditures ranged from a high of $1.1 billion in FY2024 and a low of $68.0 million during FY2020.
  • Over the past 3 years, Moderna's median Capital Expenditures value was $707.0 million (recorded in 2023), while the average stood at $719.3 million.
  • Data for Moderna's Capital Expenditures shows a peak YoY surged of 317.65% (in 2021) over the last 5 years.
  • Over the past 5 years, Moderna's Capital Expenditures (Yearly) stood at $68.0 million in 2020, then skyrocketed by 317.65% to $284.0 million in 2021, then spiked by 40.85% to $400.0 million in 2022, then spiked by 76.75% to $707.0 million in 2023, then soared by 48.66% to $1.1 billion in 2024.